Research and development targeting mobility, healthcare and other fields
First written in FY2016. 18 of 31 entries say "Restated". Latest entry: FY2026.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In October 2025, the company established development departments within the business divisions for each of its 3 growth areas and changed to a structure in which the business divisions and development organizations work more closely together, while pursuing the development of products and solutions. R&D expenses of the company and its consolidated subsidiaries for the current consolidated fiscal year were ¥46.4 billion.」
The R&D structure was changed to focus on development departments within the business divisions for the 3 growth areas, and R&D expenses totaled ¥46.4 billion. In ICT, the company continued work on EUV-related materials, semiconductor packaging, and optical technologies for AR, among other areas, while its corporate research continued to cover MI, recycling, and carbon dioxide resource utilization, among other areas. - FY2026-H1AdvancedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥23.3 billion. There were no significant changes to the Group's major research topics during the current interim consolidated accounting period.」
R&D expenses increased from ¥21.8 billion in the interim period of the previous year to ¥23.3 billion. The company continued its major research topics. - FY2025-H1AdvancedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥21.8 billion. There were no significant changes to the Group's major research topics during the current interim consolidated accounting period.」
R&D expenses increased from ¥20.5 billion in the interim period of the previous year to ¥21.8 billion, and the company continued its major research topics. - FY2024-Q3AdvancedAnnual report
「Research and development expenses of the group for the first nine months of the consolidated fiscal year were ¥32.8 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
R&D expenses increased from ¥31.2 billion in the same period of the previous year to ¥32.8 billion. The company states that there have been no significant changes to its major research topics. - FY2024-Q2AdvancedAnnual report
「Total research and development expenses for the first six months of the consolidated fiscal year were ¥21.5 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
Research and development expenses increased from ¥20.5 billion in the same period of the previous fiscal year to ¥21.5 billion. The company’s principal research themes remain unchanged. - FY2024-Q1RestatedAnnual report
「Research and development expenses of the group for the first three months of the consolidated fiscal year were ¥10.4 billion. There were no significant changes in the group’s principal research themes during the first three months of the consolidated fiscal year.」
The company recorded ¥10.4 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2023-Q3AdvancedAnnual report
「Total research and development expenses for the first nine months of the consolidated fiscal year were ¥31.2 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
Research and development expenses increased from ¥27.4 billion in the same period of the previous fiscal year to ¥31.2 billion, and the company continued its principal research themes. - FY2023-Q2RestatedAnnual report
「Total research and development expenses for the first six months of the consolidated fiscal year were ¥20.5 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
The company recorded ¥20.5 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2022AdvancedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the consolidated fiscal year were ¥38.1 billion.」
Research and development expenses increased from ¥33.8 billion in the previous fiscal year to ¥38.1 billion. The company expanded its research scope to ICT materials, robot materials, energy solutions, medical applications, chemical recycling, material recycling, biomass feedstock conversion, CCU and other areas. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the first nine months of the consolidated fiscal year were ¥27.4 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
The company recorded ¥27.4 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2022-Q2RestatedAnnual report
「Total research and development expenses for the first six months of the consolidated fiscal year were ¥17.8 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
The company recorded ¥17.8 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2022-Q1RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first three months of the consolidated fiscal year were ¥8.7 billion. There were no significant changes in the group’s principal research themes during the first three months of the consolidated fiscal year.」
The company recorded ¥8.7 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2021Research and development expenses declined, but priority areas remain unchangedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the consolidated fiscal year were ¥33.8 billion.」
Research and development expenses declined from ¥36.4 billion in the previous fiscal year to ¥33.8 billion, but the company continued research into mobility, healthcare, food and packaging, basic materials, new business creation, chemical recycling and biomass, among other areas. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the first nine months of the consolidated fiscal year were ¥24.4 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
The company recorded ¥24.4 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the first six months of the consolidated fiscal year were ¥16.3 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
The company recorded ¥16.3 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2021-Q1RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first three months of the consolidated fiscal year were ¥7.9 billion. There were no significant changes in the group’s principal research themes during the first three months of the consolidated fiscal year.」
The company recorded ¥7.9 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2020AdvancedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the consolidated fiscal year were ¥36.4 billion.」
Research and development expenses increased from ¥35.8 billion in the previous fiscal year to ¥36.4 billion. The company continued research into mobility, healthcare, food and packaging, basic materials and new business creation. - FY2020-Q3RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first nine months of the consolidated fiscal year were ¥26.9 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
The company recorded ¥26.9 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2020-Q2RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first six months of the consolidated fiscal year were ¥18.2 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
The company recorded ¥18.2 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2019AdvancedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the consolidated fiscal year were ¥35.8 billion.」
Research and development expenses increased from ¥33.4 billion in the previous fiscal year to ¥35.8 billion. The company continues research and development into lightweight materials, integrated metal-resin molding technology, battery materials, solar power generation-related technologies and other areas. - FY2019-Q3RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first nine months of the consolidated fiscal year were ¥26.4 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
The company recorded ¥26.4 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2019-Q2RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first six months of the consolidated fiscal year were ¥17.7 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
The company recorded ¥17.7 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2019-Q1RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first three months of the consolidated fiscal year were ¥8.7 billion. There were no significant changes in the group’s principal research themes during the first three months of the consolidated fiscal year.」
The company recorded ¥8.7 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2018AdvancedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the consolidated fiscal year were ¥33.4 billion.」
Research and development expenses increased from ¥30.8 billion in the previous fiscal year to ¥33.4 billion, while the company continued research and development into lightweight materials, integrated metal-resin molding technology, battery materials, solar power generation-related technologies and other areas. - FY2018-Q3RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first nine months of the consolidated fiscal year were ¥24.6 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
The company recorded ¥24.6 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2018-Q2RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first six months of the consolidated fiscal year were ¥16.2 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
The company recorded ¥16.2 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2018-Q1RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first three months of the consolidated fiscal year were ¥7.9 billion. There were no significant changes in the group’s principal research themes during the first three months of the consolidated fiscal year.」
The company recorded ¥7.9 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2017RaisedAnnual report
「Research and development expenses: ¥70 billion in fiscal 2025, approximately twice the fiscal 2016 level」
In addition to research and development expenses of ¥30.8 billion in the current fiscal year, the company added a long-term research and development investment target of ¥70 billion in fiscal 2025, approximately twice the fiscal 2016 level. - FY2017-Q3RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first nine months of the consolidated fiscal year were ¥22.4 billion. There were no significant changes in the group’s principal research themes during the first nine months of the consolidated fiscal year.」
The company recorded ¥22.4 billion in research and development expenses and reconfirmed that there were no significant changes in its principal research themes. - FY2017-Q2RestatedAnnual report
「Research and development expenses of the company and its consolidated subsidiaries for the first six months of the consolidated fiscal year were ¥14.8 billion. There were no significant changes in the group’s principal research themes during the first six months of the consolidated fiscal year.」
The company recorded ¥14.8 billion in research and development expenses and stated that there were no significant changes in its principal research themes. - FY2016First statedAnnual report
「The company is conducting project-based research and development aimed at creating new businesses in the Mobility and Healthcare areas.」
Research and development expenses for the consolidated fiscal year were ¥31.5 billion. The company is developing integrated metal-resin molded products, battery materials, solar power generation-related technologies and other products and technologies.